Adherence and Persistence with GLP-1-Based Therapies: International Real-World Evidence and the Role of Nutritional and Lifestyle Support—A Narrative Review
Open accessThe DOI matches its Crossref record; 87 of the 87 references it cites were found in a registry or an index; 108 of the 144 sources its claims cite were checked for support.
Abstract
Adherence and Adherence/Persistence with GLP-1-Based Therapies: International Real-World Evidence and the Role of Nutritional and Lifestyle Support—A Narrative Review. Global persistence varies widely: from approximately 75–80% at 12 months in reimbursed T2DM cohorts to below 10% in obesity-focused or high out-of-pocket-cost settings; in several cohorts, persistence falls below 15% by 24 months. The primary drivers are gastrointestinal intolerance and economic barriers.
Overview
CoChat Summary
TL;DR
This narrative review synthesizes international real-world evidence showing that GLP-1 receptor agonist persistence is highly variable and substantially below clinical-trial retention, driven mainly by gastrointestinal intolerance and economic barriers. It proposes integrating medical nutrition therapy and structured lifestyle/behavioral support into routine GLP-1 care, while acknowledging that most supporting evidence is extrapolated rather than derived from GLP-1-specific randomized trials.
Key findings
- Real-world persistence ranged from approximately 75–80% at 12 months in reimbursed T2DM cohorts (Sweden ~76.4%; Denmark ~78.8%) to below 10% in obesity-focused or high out-of-pocket settings (Poland 6.6% long-term persistence; Colombia 0.2% at 12 months); U.S. company-published data reported 8.1% persistence at 3 years, and UK data reported ~54.8% at 12 months and ~35.3% at 24 months.
- GI intolerance and economic barriers were the primary drivers; in STEP UP, GI adverse events occurred in ~71% with semaglutide 7.2 mg vs 61% with 2.4 mg and 43% with placebo, and a cross-sectional survey found patients most often cited nausea (64.4%) and vomiting (45.4%), while physicians most often cited inadequate glycemic control (45.6%) and nausea/vomiting (43.8%).
- The proposed nutritional framework includes protein targets of 1.2–1.5 g/kg/day in chronic illness and up to ~1.6 g/kg/day during active weight loss, resistance training 2–3 times weekly, nutrient-dense lower-volume meals, and micronutrient screening; U.S. Medicare MNT coverage excludes obesity without T2DM or CKD.
- Cardiovascular benefit may be partly independent of weight loss: SELECT showed a 20% MACE reduction, and a prespecified analysis suggested waist-circumference reduction mediated only approximately one-third of the treatment effect.
Methods
- Narrative review using PubMed as the primary database, supplemented by Embase, Google Scholar, and hand-searching; English-language publications from inception through 31 January 2026 in adults ≥19 years. The primary PubMed search identified 5523 records, reduced to 3935 human studies and 2138 adult studies, with 87 publications included in the final synthesis.
- Eligible sources included RCTs, prospective/retrospective cohorts, insurance claims and pharmacy benefit analyses, national registry studies, systematic reviews/meta-analyses, and consensus documents; exclusions included non-English publications, pediatric-only studies, single case reports unless illustrating a novel mechanistic concept, and non-peer-reviewed grey literature except labeled company-reported real-world evidence.
- No formal risk-of-bias assessment, GRADE rating, or meta-analytic synthesis was performed; studies were selected by topical relevance, prioritizing landmark RCTs, large real-world cohort/claims analyses, and recent 2023–2026 primary publications.
Limitations
- Stated: as a narrative rather than systematic review, selection and synthesis are subject to selection bias; no formal risk-of-bias assessment, GRADE rating, or meta-analysis was performed. Persistence definitions, allowable gap thresholds (60 vs 90 days), follow-up durations, and data sources differ across studies, precluding direct quantitative cross-cohort comparison, and the evidence base is predominantly from high-income settings, limiting generalizability to low- and middle-income countries.
- Stated: many nutritional and behavioral recommendations are extrapolated from related populations or expert consensus rather than GLP-1-specific randomized trials; direct randomized evidence for integrated MNT/behavioral support improving persistence is limited. The microbiota evidence comes from a single 60-day RCT in 25 adults, the neuroimaging evidence is a single-patient case, and the dietary volume/gastric-stasis mechanism has not been tested in randomized dietary-modification trials within GLP-1 RA cohorts.
- Evident: the review includes company-published, non-peer-reviewed real-world data (e.g., Prime Therapeutics, Omada Health), and the Omada cohort was self-selected, digitally engaged, and commercially insured; the AI-driven lifestyle RCT was conducted in a non-GLP-1-using population, and several cited sources are cross-sectional surveys or single-case observations, limiting causal inference.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
65 Valid · 8 Not valid · 25 Not checked · 49 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“When a patient receiving a high-dose GLP-1 RA consumes a high-fat meal, the combined effect of pharmacological and endogenous lipid-mediated signaling can produce profound gastric stasis [27,33].”
§ Adherence and Persistence with GLP-1-Based Therapies: International Real-World Evidence and the Role of Nutritional and Lifestyle Support—A Narrative Review > 3. Physiology of GLP-1 and Nutritional Interaction > 3.2. Nutritional Feedback Loops and Adverse Events
What the sources say
- Partly supportedcites [27] Mozaffarian, 2025, Nutritional Priorities to Support GLP-1 Therapy for Obesity: A Joint Advisory From the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and the Obesity Society, Am. J. Lifestyle Med. sourceExperimental — accuracy not yet measured
The Side effects section says GLP-1 therapy delays gastric emptying and that higher doses are more likely to cause GI symptoms. The Management of GI side effects section says fatty foods can further slow gastric emptying, while Dietary modulation of GLP-1 release and action says certain fatty acids stimulate endogenous GLP-1 release. The paper does not establish that these effects combine in a high-dose patient after a high-fat meal to produce profound gastric stasis. Page numbers were not available in our copy. (LLM, conf=0.87)
- Partly supportedcites [33] Gentinetta, 2024, Dietary Recommendations for the Management of Gastrointestinal Symptoms in Patients Treated with GLP-1 Receptor Agonist, Diabetes Metab. Syndr. Obes. sourceExperimental — accuracy not yet measured
The GLP-1 Receptor Agonists and Their Adverse Events section says GLP-1RAs delay gastric emptying and that fatty acids can increase endogenous GLP-1 levels. The Results > Fats section says fats may also delay gastric emptying. Neither section establishes that a high-fat meal combined with a high-dose GLP-1RA produces profound gastric stasis, or attributes that outcome to combined signaling. Page numbers are unavailable in our copy. (LLM, conf=0.86)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Yet the dominant physiological driver of discontinuation and non-persistence remains gastrointestinal (GI) intolerance, an intrinsic consequence of GLP-1 receptor activation in the gut and brainstem [23,24].”
§ Adherence and Persistence with GLP-1-Based Therapies: International Real-World Evidence and the Role of Nutritional and Lifestyle Support—A Narrative Review > 1. Introduction
What the sources say
- Partly supportedcites [23] Aldhaleei, W.A., Abegaz, T.M., and Bhagavathula, A.S. (2024). Glucagon-like Peptide-1 Receptor Agonists Associated Gastrointestinal Adverse Events: A Cross-Sectional Analysis of the National Institutes of Health All of Us Cohort. Pharmaceuticals, 17. sourceExperimental — accuracy not yet measured
The Results (§2.3; page not provided) report frequent gastrointestinal adverse events among GLP-1 RA users, and the Discussion (§3) describes differences in GI tolerability between agents. The paper does not establish that GI intolerance is the dominant driver of discontinuation or non-persistence, or attribute it to receptor activation in the gut and brainstem. (LLM, conf=0.86)
- Partly supportedcites [24] Ismaiel, 2025, Gastrointestinal Adverse Events Associated with GLP-1 RA in Non-Diabetic Patients with Overweight or Obesity: A Systematic Review and Network Meta-Analysis, Int. J. Obes. sourceExperimental — accuracy not yet measured
The Discussion (page not provided) says persistent gastrointestinal symptoms can lead to treatment discontinuation and affect adherence. It does not establish GI intolerance as the dominant driver of discontinuation or non-persistence. The Introduction (page not provided) says the mechanism remains incompletely understood and discusses gastrointestinal motility and secretion, not a demonstrated gut-and-brainstem mechanism. (LLM, conf=0.88)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources that could be checked couldn’t confirm or dispute this claim.
In the paper
“whether lean-mass loss itself directly precipitates early treatment discontinuation, however, has not been established [25,26].”
§ Adherence and Persistence with GLP-1-Based Therapies: International Real-World Evidence and the Role of Nutritional and Lifestyle Support—A Narrative Review > 1. Introduction
What the sources say
- Could not verifycites [25] Jensen, 2024, Bone Health After Exercise Alone, GLP-1 Receptor Agonist Treatment, or Combination Treatment: A Secondary Analysis of a Randomized Clinical Trial, JAMA Netw. Open sourceExperimental — accuracy not yet measured
The Results sections on Body Weight and Body Composition and Compliance report lean-mass changes and medication discontinuations separately, without examining whether one caused the other. Our copy does not state whether a direct link between lean-mass loss and early treatment discontinuation has been established; searches for that link and for discontinuation did not find one. The indexed passages provide no page numbers. (LLM, conf=0.72)
- Could not verifycites [26] Sato, 2025, Muscle Loss in Obesity Therapy as a Therapeutic Target: Trial Design and Endpoints for Regulatory Discussions, J. Cachexia Sarcopenia Muscle sourceExperimental — accuracy not yet measured
The ‘Weight Regain After Intervention Withdrawal’ section reports that fewer than half of patients remain on these medications after one year, while the ‘Incretins and Muscle Loss’ section discusses lean-tissue loss. Neither section addresses whether lean-mass loss causes early discontinuation or explicitly says that this relationship has not been established. Searched for reasons for withdrawal, adherence, and discontinuation due to muscle or lean-mass loss; page numbers were not available in our copy. (LLM, conf=0.70)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Could not verify
Every source the paper cites for this claim was checked and supports it.
In the paper
“A dose–response relationship exists between cost-sharing and adherence: patients in the highest out-of-pocket cost quartiles have significantly greater odds of nonadherence [57].”
§ Adherence and Persistence with GLP-1-Based Therapies: International Real-World Evidence and the Role of Nutritional and Lifestyle Support—A Narrative Review > 5. Barriers to Adherence and Persistence with GLP-1 Therapy > 5.2. Economic and Structural Barriers
What the sources say
- Supportedcites [57] Zhang, 2025, Association of Patient Cost Sharing With Adherence to GLP-1RA and Adverse Health Outcomes, Diabetes Care source
The Results report a significant monotonic relationship between out-of-pocket costs and proportion of days covered. Table 2 also shows significantly higher odds of GLP-1RA nonadherence in the highest cost quartile than in the lowest (OR 1.25, 95% CI 1.19–1.31) among adults with type 2 diabetes. (LLM, conf=0.91)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“This coverage gap creates a paradox in which patients receive highly potent pharmacotherapies without financial access to the nutritional expertise required to use them safely and effectively [65].”
§ Adherence and Persistence with GLP-1-Based Therapies: International Real-World Evidence and the Role of Nutritional and Lifestyle Support—A Narrative Review > 6. Nutritional Support Strategies > 6.1. The Academy of Nutrition and Dietetics Position Statement and Pharmacoeconomic Implications
What the sources say
- Partly supportedcites [65] Rowland, 2025, Expansion of Medicare Coverage for Medical Nutrition Therapy, JAMA Netw. Open sourceExperimental — accuracy not yet measured
The Introduction (page unavailable) says Medicare covers dietitian-provided medical nutrition therapy only for specified conditions, and the Results (page unavailable) show that proposed expansion would increase eligibility from 30.3% to 85.1% of beneficiaries. This supports a coverage gap, but the paper does not say patients receive potent pharmacotherapies or that nutritional expertise is required to use those drugs safely and effectively. (LLM, conf=0.86)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
56 more claims · 26 with their cited sources checked
Create a free account to see all 147 claims and to verify the 5 references still open.
- It may state two separate claims as one. 74
- Probably not a substantial claim. 21
- The quote only partly states this claim. 1
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated major: it would touch a result — a value a result rests on, reported and recomputed p-values on opposite sides of the significance level, two passages that conflict with no sign which is right, or a cited work retracted before this paper was published.
In the paper
§ Adherence and Persistence with GLP-1-Based Therapies: International Real-World Evidence and the Role of Nutritional and Lifestyle Support—A Narrative Review > 5. Barriers to Adherence and Persistence with GLP-1 Therapy > 5.2. Economic and Structural Barriers
“persistence fell from 35.4% at one month to 13.8% at six months and 0.2% at twelve months”
§ Adherence and Persistence with GLP-1-Based Therapies: International Real-World Evidence and the Role of Nutritional and Lifestyle Support—A Narrative Review > 4. Global Epidemiology of Adherence and Persistence > 4.4. Latin America
“35.4% abandoned treatment after a single month”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Adherence and Persistence with GLP-1-Based Therapies: International Real-World Evidence and the Role of Nutritional and Lifestyle Support—A Narrative Review > 6. Nutritional Support Strategies > 6.1. The Academy of Nutrition and Dietetics Position Statement and Pharmacoeconomic Implications
“In a position paper published in late 2025, the Academy of Nutrition and Dietetics stated that all individuals receiving obesity pharmacotherapy should have concurrent access to evidence-based MNT delivered by a registered dietitian nutritionist (RDN) [27].”
§ Adherence and Persistence with GLP-1-Based Therapies: International Real-World Evidence and the Role of Nutritional and Lifestyle Support—A Narrative Review > References
“27. Mozaffarian D. Agarwal M. Aggarwal M. Alexander L. Apovian C.M. Bindlish S. Bonnet J. Butsch W.S. Christensen S. Gianos E. Nutritional Priorities to Support GLP-1 Therapy for Obesity: A Joint Advisory From the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and the Obesity Society”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Adherence and Persistence with GLP-1-Based Therapies: International Real-World Evidence and the Role of Nutritional and Lifestyle Support—A Narrative Review > 2. Methods > 2.3. Inclusion and Exclusion Criteria
“Exclusion criteria comprised non-English-language publications, studies conducted exclusively in pediatric populations, single case reports unless illustrating a novel mechanistic concept (e.g., the neuroimaging case study cited in Section 5.3), and non-peer-reviewed grey literature, except where explicitly labeled as company-reported real-world evidence.”
§ Adherence and Persistence with GLP-1-Based Therapies: International Real-World Evidence and the Role of Nutritional and Lifestyle Support—A Narrative Review > References
“60. Dang V. Sambuco N. Yammine L. Versace F. Do GLP-1 Receptor Agonists Alter Brain Responses to Reward-Related Cues? A Systematic Review bioRxiv 2026 10.64898/2026.01.31.702984”
Citations
Cites
Once-Weekly Semaglutide in Adults with Overweight or Obesity
Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., McGowan, B. M., Rosenstock, J., Tran, M. T. D., Wadden, T. A., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2032183 · Cited by 5,205 · cited 3×
“The most successful weight-loss trials to date—including the STEP program for semaglutide [9] and the SURMOUNT program for tirzepatide [13]—have incorporated intensive lifestyle interventions as a core component of the trial protocol, modeled on the structured behavioral curricula pioneered by the…”
Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes
Lincoff, A. M., Brown-Frandsen, K., Colhoun, H. M., Deanfield, J., Emerson, S. S., Esbjerg, S., Hardt-Lindberg, S., Hovingh, G. K., Kahn, S. E., Kushner, R. F., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2307563 · Cited by 3,236 · cited 3×
“Furthermore, landmark trials such as SELECT have confirmed significant reductions in major adverse cardiovascular events (MACE), establishing these agents as systemic disease-modifying therapies beyond glycemic and weight control [7,14,15].”
Diabetes Prevention Program Research Group (2009) · The Lancet · doi:10.1016/s0140-6736(09)61457-4 · Cited by 3,020 · cited 1×
“…date—including the STEP program for semaglutide [9] and the SURMOUNT program for tirzepatide [13]—have incorporated intensive lifestyle interventions as a core component of the trial protocol, modeled on the structured behavioral curricula pioneered by the Diabetes Prevention Program (DPP) [76,77].”
Bauer, J., Biolo, G., Cederholm, T., Cesari, M., Cruz-Jentoft, A. J., Morley, J. E., Phillips, S., Sieber, C., Stehle, P., Teta, D., et al. (2013) · Journal of the American Medical Directors Association · doi:10.1016/j.jamda.2013.05.021 · Cited by 2,553
How are habits formed: modelling habit formation in the real world
Lally, P., van Jaarsveld, C. H. M., Potts, H. W. W., & Wardle, J. (2010) · European Journal of Social Psychology · doi:10.1002/ejsp.674 · Cited by 2,036 · cited 1×
“While nutritional strategies address the physiological side effects of GLP-1 RAs, behavioral interventions target the psychological barriers and habit-formation processes critical for long-term persistence [80–82].”
Glucagon-like peptide 1 (GLP-1)
Müller, T. D., Finan, B., Bloom, S. R., D'Alessio, D., Drucker, D. J., Flatt, P. R., Fritsche, A., Gribble, F., Grill, H. J., Habener, J. F., et al. (2019) · Molecular Metabolism · doi:10.1016/j.molmet.2019.09.010 · Cited by 1,868
Deutz, N. E. P., Bauer, J. M., Barazzoni, R., Biolo, G., Boirie, Y., Bosy-Westphal, A., Cederholm, T., Cruz-Jentoft, A., Krznariç, Z., Nair, K. S., et al. (2014) · Clinical Nutrition · doi:10.1016/j.clnu.2014.04.007 · Cited by 1,738 · cited 1×
“…position paper, synthesizing nitrogen-balance and clinical-outcome studies, recommends a minimum daily intake of 1.0–1.2 g/kg/day for healthy older adults and 1.2–1.5 g/kg/day for those with acute or chronic illness [68]; corresponding ESPEN consensus recommendations align closely [69].”
InfluentialRosenstock, J., Wysham, C., Frías, J. P., Kaneko, S., Lee, C. J., Fernández Landó, L., Mao, H., Cui, X., Karanikas, C. A., & Thieu, V. T. (2021) · The Lancet · doi:10.1016/s0140-6736(21)01324-6 · Cited by 1,080 · cited 1×
“Foundational studies such as STEP [9,10] and SURPASS [11,12] established high benchmarks for weight reduction, while recent data from the SURMOUNT-5 [13] head-to-head trial demonstrated that dual agonism with tirzepatide can achieve mean body weight reductions exceeding 20%.”
Lifestyle modification approaches for the treatment of obesity in adults.
Wadden, T. A., Tronieri, J. S., & Butryn, M. L. (2020) · American Psychologist · doi:10.1037/amp0000517 · Cited by 661
Tirzepatide as Compared with Semaglutide for the Treatment of Obesity
Aronne, L. J., Horn, D. B., le Roux, C. W., Ho, W., Falcon, B. L., Gomez Valderas, E., Das, S., Lee, C. J., Glass, L. C., Senyucel, C., et al. (2025) · New England Journal of Medicine · doi:10.1056/nejmoa2416394 · Cited by 634 · cited 2×
“The most successful weight-loss trials to date—including the STEP program for semaglutide [9] and the SURMOUNT program for tirzepatide [13]—have incorporated intensive lifestyle interventions as a core component of the trial protocol, modeled on the structured behavioral curricula pioneered by the…”
Preserving Healthy Muscle during Weight Loss
Cava, E., Yeat, N. C., & Mittendorfer, B. (2017) · Advances in Nutrition · doi:10.3945/an.116.014506 · Cited by 452 · cited 3×
“This approach is supported by the broader food-first framework for post-exercise muscle protein synthesis [73] and by evidence that distributing protein intake of approximately 25–30 g across each of three to four daily meals maximizes the muscle protein synthetic response in adults [68,70].”
InfluentialRodriguez, P. J., Zhang, V., Gratzl, S., Do, D., Goodwin Cartwright, B., Baker, C., Gluckman, T. J., Stucky, N., & Emanuel, E. J. (2025) · JAMA Network Open · doi:10.1001/jamanetworkopen.2024.57349 · Cited by 374 · cited 1×
“Another U.S. cohort study found that 46.5% of patients with T2DM and 64.8% of patients with obesity discontinued treatment within one year [19].”
InfluentialGorgojo-Martínez, J. J., Mezquita-Raya, P., Carretero-Gómez, J., Castro, A., Cebrián-Cuenca, A., de Torres-Sánchez, A., García-de-Lucas, M. D., Núñez, J., Obaya, J. C., Soler, M. J., et al. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm12010145 · Cited by 358 · cited 2×
“…to inhibit gastric emptying, reducing fat load per meal is a physiologically plausible and commonly recommended strategy to reduce postprandial nausea and fullness during GLP-1 RA titration, although randomized dietary-modification trials specifically in GLP-1-treated cohorts are lacking [66,67].”
Semaglutide for the treatment of overweight and obesity: A review
Bergmann, N. C., Davies, M. J., Lingvay, I., & Knop, F. K. (2023) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14863 · Cited by 265 · cited 1×
“Foundational studies such as STEP [9,10] and SURPASS [11,12] established high benchmarks for weight reduction, while recent data from the SURMOUNT-5 [13] head-to-head trial demonstrated that dual agonism with tirzepatide can achieve mean body weight reductions exceeding 20%.”
Mechanisms of action and therapeutic applications of GLP-1 and dual GIP/GLP-1 receptor agonists
Liu, Q. K. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1431292 · Cited by 265 · cited 4×
“Therapeutic GLP-1 RAs are resistant to this enzymatic degradation, providing supraphysiological levels of receptor activation over extended periods [29,30].”
InfluentialDelgado-Aros, S., Kim, D.-Y., Burton, D. D., Thomforde, G. M., Stephens, D., Brinkmann, B. H., Vella, A., & Camilleri, M. (2002) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.2002.282.3.g424 · Cited by 235
Alfaris, N., Waldrop, S., Johnson, V., Boaventura, B., Kendrick, K., & Stanford, F. C. (2024) · EClinicalMedicine · doi:10.1016/j.eclinm.2024.102782 · Cited by 224 · cited 2×
“However, a critical dichotomy has emerged between the highly supervised environment of RCTs and the realities of routine clinical practice [4,5,16–18].”
Sikirica, M., Martin, A., Wood, R., Leith, A., Piercy, J., & Higgins, V. (2017) · Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy · doi:10.2147/dmso.s141235 · Cited by 223 · cited 1×
“In the largest cross-sectional survey of GLP-1 RA discontinuation in routine practice to date, both physicians and patients converged on GI symptoms as a leading cause of treatment cessation, although the relative emphasis differed [54].”
Cardiovascular outcomes with tirzepatide versus dulaglutide in type 2 diabetes
Nicholls, S. J., Pavo, I., Bhatt, D. L., Buse, J. B., Del Prato, S., Kahn, S. E., Lincoff, A. M., McGuire, D. K., Miller, D., Nauck, M. A., et al. (2025) · New England Journal of Medicine · doi:10.1056/nejmoa2505928 · Cited by 223 · cited 1×
“Foundational studies such as STEP [9,10] and SURPASS [11,12] established high benchmarks for weight reduction, while recent data from the SURMOUNT-5 [13] head-to-head trial demonstrated that dual agonism with tirzepatide can achieve mean body weight reductions exceeding 20%.”
Religioni, U., Barrios-Rodríguez, R., Requena, P., Borowska, M., & Ostrowski, J. (2025) · Medicina · doi:10.3390/medicina61010153 · Cited by 215 · cited 1×
“Adherence refers to conformity with dosing recommendations, often measured by the proportion of days covered (PDC), while persistence refers to the continuity of therapy over time [39].”
Thomsen, R. W., Mailhac, A., Løhde, J. B., & Pottegård, A. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16364 · Cited by 207 · cited 2×
“…real-world evidence from diverse healthcare systems—ranging from the insurance-based models of the United States to the single-payer systems of Scandinavia and the United Kingdom—consistently indicates that a substantial proportion of patients discontinue therapy within the first year [16,18–20].”
Resistance Training Conserves Fat-Free Mass and Resting Energy Expenditure Following Weight Loss
Hunter, G. R., Byrne, N. M., Sirikul, B., Fernández, J. R., Zuckerman, P. A., Darnell, B. E., & Gower, B. A. (2008) · Obesity · doi:10.1038/oby.2008.38 · Cited by 173 · cited 1×
“Resistance training directly counteracts the disproportionate loss of fat-free mass and the decline in resting energy expenditure (adaptive thermogenesis) that accompany rapid weight loss [25,70,78].”
Gleason, P. P., Urick, B. Y., Marshall, L. Z., Friedlander, N., Qiu, Y., & Leslie, R. S. (2024) · Journal of Managed Care & Specialty Pharmacy · doi:10.18553/jmcp.2024.23332 · Cited by 172
Richard, J. E., Anderberg, R. H., Göteson, A., Gribble, F. M., Reimann, F., & Skibicka, K. P. (2015) · PLOS ONE · doi:10.1371/journal.pone.0119034 · Cited by 168 · cited 1×
“GLP-1 receptors are densely expressed in the hypothalamus (arcuate nucleus) and the hindbrain (area postrema and nucleus of the solitary tract), where their activation enhances satiety signaling and attenuates the hedonic drive for food [31].”
Jensen, S. B. K., Sørensen, V., Sandsdal, R. M., Lehmann, E. W., Lundgren, J. R., Juhl, C. R., Janus, C., Ternhamar, T., Stallknecht, B. M., Holst, J. J., et al. (2024) · JAMA Network Open · doi:10.1001/jamanetworkopen.2024.16775 · Cited by 155
Mozaffarian, D., Agarwal, M., Aggarwal, M., Alexander, L., Apovian, C. M., Bindlish, S., Bonnet, J., Butsch, W. S., Christensen, S., Gianos, E., et al. (2025) · The American Journal of Clinical Nutrition · doi:10.1016/j.ajcnut.2025.04.023 · Cited by 154
Celletti, F., Farrar, J., & De Regil, L. (2026) · JAMA · doi:10.1001/jama.2025.24288 · Cited by 153 · cited 2×
“…policy milestone in December 2025, when the World Health Organization issued its first global guideline conditionally recommending GLP-1 therapies for weight management, formally reinforcing the recognition of obesity as a chronic, relapsing disease requiring sustained, structured care [6].”
Weiss, T., Yang, L., Carr, R. D., Pal, S., Sawhney, B., Boggs, R., Rajpathak, S., & Iglay, K. (2022) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2021-002517 · Cited by 152 · cited 1×
“Recent UK data [45] indicate intermediate persistence in a T2DM cohort (approximately 54.8% at 12 months and 35.3% at 24 months), with a median time to discontinuation of 426 days.”
InfluentialDeanfield, J., Lincoff, A. M., Kahn, S. E., Emerson, S. S., Lingvay, I., Scirica, B. M., Plutzky, J., Kushner, R. F., Colhoun, H. M., Hovingh, G. K., et al. (2025) · The Lancet · doi:10.1016/s0140-6736(25)01375-3 · Cited by 143 · cited 4×
“The SELECT trial demonstrated a 20% reduction in MACE among patients with obesity and established cardiovascular disease [15,85].”
InfluentialBurd, N. A., Beals, J. W., Martinez, I. G., Salvador, A. F., & Skinner, S. K. (2019) · Sports Medicine · doi:10.1007/s40279-018-1009-y · Cited by 127 · cited 1×
“This approach is supported by the broader food-first framework for post-exercise muscle protein synthesis [73] and by evidence that distributing protein intake of approximately 25–30 g across each of three to four daily meals maximizes the muscle protein synthetic response in adults [68,70].”
Wharton, S., Freitas, P., Hjelmesæth, J., Kabisch, M., Kandler, K., Lingvay, I., Quiroga, M., Rosenstock, J., & Garvey, W. T. (2025) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(25)00226-8 · Cited by 119
Berg, S., Stickle, H., Rose, S. J., & Nemec, E. C. (2025) · Obesity Reviews · doi:10.1111/obr.13929 · Cited by 111
GLP-1 Influences Food and Drug Reward
Hayes, M. R., & Schmidt, H. D. (2016) · Current Opinion in Behavioral Sciences · doi:10.1016/j.cobeha.2016.02.005 · Cited by 108 · cited 1×
“Activation of central GLP-1 receptors attenuates these dopamine-mediated reward pathways, reducing the incentive salience of food [59].”
Ismaiel, A., Scarlata, G. G. M., Boitos, I., Leucuta, D.-C., Popa, S.-L., Al Srouji, N., Abenavoli, L., & Dumitrascu, D. L. (2025) · International Journal of Obesity · doi:10.1038/s41366-025-01859-6 · Cited by 99 · cited 2×
“Yet the dominant physiological driver of discontinuation and non-persistence remains gastrointestinal (GI) intolerance, an intrinsic consequence of GLP-1 receptor activation in the gut and brainstem [23,24].”
Sikand, G., Cole, R. E., Handu, D., deWaal, D., Christaldi, J., Johnson, E. Q., Arpino, L. M., & Ekvall, S. M. (2018) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2018.06.016 · Cited by 84 · cited 1×
“…of multiple individual MNT sessions delivered by RDN demonstrated clinically meaningful improvements in lipids, glycemia, body mass index, and blood pressure, together with reduced need for lipid-lowering medications and net cost savings primarily driven by reduced medication use [63].”
Aldhaleei, W. A., Abegaz, T. M., & Bhagavathula, A. S. (2024) · Pharmaceuticals · doi:10.3390/ph17020199 · Cited by 80 · cited 1×
“Yet the dominant physiological driver of discontinuation and non-persistence remains gastrointestinal (GI) intolerance, an intrinsic consequence of GLP-1 receptor activation in the gut and brainstem [23,24].”
What Is Food Noise? A Conceptual Model of Food Cue Reactivity
Hayashi, D., Edwards, C., Emond, J. A., Gilbert-Diamond, D., Butt, M., Rigby, A., & Masterson, T. D. (2023) · Nutrients · doi:10.3390/nu15224809 · Cited by 80 · cited 2×
“The etiology of this discontinuation is multifactorial, involving socioeconomic barriers, prohibitive out-of-pocket costs, supply chain fragility, and psychological factors, including the resurgence of appetitive drive (commonly termed “food noise”) upon missed doses [21,22].”
Lifetime Health Effects and Cost-Effectiveness of Tirzepatide and Semaglutide in US Adults
Hwang, J. H., Laiteerapong, N., Huang, E. S., & Kim, D. D. (2025) · JAMA Health Forum · doi:10.1001/jamahealthforum.2024.5586 · Cited by 77 · cited 1×
“…obesity have lifetime incremental cost-effectiveness ratios of approximately USD 197,000 and USD 468,000 per quality-adjusted life-year, respectively—values that would require price discounts of 30.5% (tirzepatide) and 81.9% (semaglutide) to reach the conventional USD 100,000/QALY threshold [56].”
InfluentialLevi, J., Wang, J., Venter, F., & Hill, A. (2023) · Obesity · doi:10.1002/oby.23725 · Cited by 69 · cited 1×
“…analysis of estimated minimum production costs suggested that semaglutide could be supplied at approximately USD 40 per 30-day course, indicating that current national prices primarily reflect manufacturer pricing strategy and patent protection rather than cost-of-goods constraints [55].”
Scott Butsch, W., Sulo, S., Chang, A. T., Kim, J. A., Kerr, K. W., Williams, D. R., Hegazi, R., Panchalingam, T., Goates, S., & Heymsfield, S. B. (2025) · Obesity Pillars · doi:10.1016/j.obpill.2025.100186 · Cited by 58
Effect of Glucagon-like Peptide-1 Receptor Antagonism on Appetite and Food Intake in Healthy Men
Steinert, R. E., Schirra, J., Meyer-Gerspach, A. C., Kienle, P., Fischer, H., Schulte, F., Goeke, B., & Beglinger, C. (2014) · The American Journal of Clinical Nutrition · doi:10.3945/ajcn.114.083246 · Cited by 52 · cited 1×
“Dietary lipids are potent stimulators of endogenous gut hormones, including cholecystokinin and peptide YY, which act synergistically with GLP-1 to inhibit gastric emptying [35].”
Hu, E.-H., Tsai, M.-L., Lin, Y., Chou, T.-S., & Chen, T.-H. (2024) · Medicina · doi:10.3390/medicina60030357 · Cited by 43 · cited 1×
“…agents to the current dominance of long-acting analogues, including semaglutide and the dual glucose-dependent insulinotropic polypeptide (GIP)/GLP-1 RA tirzepatide, these pharmacotherapies have expanded the non-surgical treatment options available for obesity and cardiometabolic disease [3–5].”
Mathioudakis, N., Lalani, B., Abusamaan, M. S., Alderfer, M., Alver, D., Dobs, A., Kane, B., McGready, J., Riekert, K., Ringham, B., et al. (2025) · JAMA · doi:10.1001/jama.2025.19563 · Cited by 41 · cited 2×
“…designed RCT, Mathioudakis et al. (2025) compared a fully autonomous artificial intelligence (AI)-driven lifestyle-intervention application against traditional human coaching within a digital Diabetes Prevention Program (d-DPP) framework, in adults with prediabetes, overweight, or obesity [84].”
Novel GLP-1-based Medications for Type 2 Diabetes and Obesity
Son, J. W., le Roux, C. W., Blüher, M., Nauck, M. A., & Lim, S. (2026) · Endocrine Reviews · doi:10.1210/endrev/bnaf036 · Cited by 40 · cited 1×
“The therapeutic landscape for metabolic diseases—encompassing type 2 diabetes mellitus (T2DM), obesity, and their cardiovascular sequelae—has been fundamentally transformed by the widespread adoption of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) [1,2].”
Lassen, M. C. H., Johansen, N. D., Modin, D., Catarig, A., Vistisen, B. K., Amadid, H., Zimmermann, E., Gislason, G., & Biering‐Sørensen, T. (2024) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.15872 · Cited by 40 · cited 2×
“%) and a 6-month discontinuation risk of 14.2% [48].”
InfluentialUrbina, J., Salinas‐Ruiz, L. E., Valenciano, C., & Clapp, B. (2026) · Clinical Obesity · doi:10.1111/cob.70070 · Cited by 40 · cited 1×
“Consequently, patients are at heightened risk for deficiencies in iron, vitamin B 12 , calcium, vitamin D, and zinc [74].”
Yamanouchi, D. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms27010027 · Cited by 40
Mohr, A. E., Hatem, C., Sikand, G., Rozga, M., Moloney, L., Sullivan, J., De Waal, D., & Handu, D. (2022) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2022.06.008 · Cited by 34 · cited 1×
“A more recent systematic review and meta-analysis confirmed and extended these findings [64].”
Kadowaki, T., Heftdal, L. D., Ko, H., Overvad, M., Shimomura, I., Thamattoor, U. K., Kim, K. K., OASIS 2 Investigators, Kunishige, H., Okude, J., et al. (2025) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2025.3599 · Cited by 34 · cited 1×
“Independent of this question, oral formulations evaluated in East Asian cohorts (e.g., oral semaglutide in the OASIS 2 trial) represent a clinically relevant option for patients who prefer non-injectable therapy [51,52].”
GLP-1 receptor agonism: a transformative approach for managing type-2 diabetes and obesity
Alharbi, A. (2025) · Saudi Pharmaceutical Journal · doi:10.1007/s44446-025-00038-y · Cited by 34
Gentinetta, S., Sottotetti, F., Manuelli, M., & Cena, H. (2024) · Diabetes, Metabolic Syndrome and Obesity · doi:10.2147/dmso.s494919 · Cited by 32 · cited 8×
“When a patient receiving a high-dose GLP-1 RA consumes a high-fat meal, the combined effect of pharmacological and endogenous lipid-mediated signaling can produce profound gastric stasis [27,33].”
InfluentialRondanelli, M., Miraglia, N., Putignano, P., Castagliuolo, I., Brun, P., Dall’Acqua, S., Peroni, G., Faliva, M. A., Naso, M., Nichetti, M., et al. (2021) · Nutrients · doi:10.3390/nu13082512 · Cited by 31 · cited 1×
“The study demonstrated that supplementation with the yeast Saccharomyces boulardii combined with superoxide dismutase resulted in significant reductions in total body weight, fat mass, fasting insulin, uric acid, and the HOMA-IR index [75].”
Crandall, J. P., Dabelea, D., Knowler, W. C., Nathan, D. M., Temprosa, M., DPP Research Group, Bray, G. A., Gadde, K. M., Culbert, I. W., Arceneaux, J., et al. (2025) · Diabetes Care · doi:10.2337/dc25-0014 · Cited by 29 · cited 1×
“…date—including the STEP program for semaglutide [9] and the SURMOUNT program for tirzepatide [13]—have incorporated intensive lifestyle interventions as a core component of the trial protocol, modeled on the structured behavioral curricula pioneered by the Diabetes Prevention Program (DPP) [76,77].”
Kong, F., Zhao, Y., Zhang, W., Wang, X., Wu, T., Zhou, Z., Xu, Y., Xia, L., & Sun, T. (2026) · Nature Communications · doi:10.1038/s41467-025-67701-9 · Cited by 29 · cited 2×
“Furthermore, landmark trials such as SELECT have confirmed significant reductions in major adverse cardiovascular events (MACE), establishing these agents as systemic disease-modifying therapies beyond glycemic and weight control [7,14,15].”
Lim, C.-E., Pasternak, B., Eliasson, B., & Ueda, P. (2025) · Diabetologia · doi:10.1007/s00125-025-06439-x · Cited by 27 · cited 1×
“…of discontinuation identical to that used in the Polish data described below, reported a cumulative discontinuation incidence of 23.6% at one year and 38.5% at three years—corresponding to one-year persistence of approximately 76.4% and three-year persistence of approximately 61.5% [43,44].”
InfluentialRadwan, R. M., Lee, Y. A., Kotecha, P., Wright, D. R., Hernandez, I., Ramon, R., Donahoo, W. T., Chen, Y., Allen, J. M., Bian, J., et al. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16318 · Cited by 24
Yamanouchi, D. (2025) · doi:10.20944/preprints202511.1408.v2 · Cited by 23
Kansakar, U., Jankauskas, S. S., Pande, S., Mone, P., Varzideh, F., & Santulli, G. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27031409 · Cited by 22
Aamir, A. B., Latif, R., Alqoofi, J. F., Almarzoq, F. A., Fallatah, J. O., Hassan, G. A., & Saab, F. A. A. A. A. (2025) · Journal of Clinical Medicine Research · doi:10.14740/jocmr6231 · Cited by 19 · cited 2×
“Randomized clinical trials (RCTs) have consistently demonstrated efficacy profiles previously unattainable with non-surgical interventions [4,7,8].”
Mozaffarian, D., Agarwal, M., Aggarwal, M., Alexander, L. C., Apovian, C. M., Bindlish, S., Bonnet, J., Butsch, W. S., Christensen, S., Gianos, E., et al. (2025) · American Journal of Lifestyle Medicine · doi:10.1177/15598276251344827 · Cited by 19
Sarpatwari, A., Soto, M. J., Ganguli, I., Sloan, C. E., Goss, F., & Sinaiko, A. D. (2025) · JAMA Health Forum · doi:10.1001/jamahealthforum.2025.4258 · Cited by 18
Kalayci, A., Januzzi, J. L., Mitsunami, M., Tanboga, I. H., Karabay, C. Y., & Gibson, C. M. (2025) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvaf037 · Cited by 18 · cited 1×
“These data indicate that GLP-1 RAs function primarily as direct vascular and systemic disease-modifying agents, operating through anti-inflammatory pathways and endothelial stabilization, rather than solely through adiposity reduction [85,87].”
Dietary and Behavioral Strategies for Weight Loss and Weight Loss Maintenance: A Narrative Review
Żurawski, T., & Bartosiewicz, A. (2025) · Nutrients · doi:10.3390/nu18010012 · Cited by 18
Svensson, A., Toll, A., Lebrec, J., Miftaraj, M., Franzén, S., & Eliasson, B. (2021) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14276 · Cited by 17 · cited 1×
“…of discontinuation identical to that used in the Polish data described below, reported a cumulative discontinuation incidence of 23.6% at one year and 38.5% at three years—corresponding to one-year persistence of approximately 76.4% and three-year persistence of approximately 61.5% [43,44].”
InfluentialTargeting Sarcopenia in CKD: The Emerging Role of GLP-1 Receptor Agonists
Llinares-Arvelo, V., Martínez‐Alberto, C. E., González-Luis, A., Macía-Heras, M., Siverio-Morales, O., Navarro‐González, J. F., & Donate‐Correa, J. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26168096 · Cited by 15 · cited 1×
“…actual body weight, to avoid physiologically excessive protein prescriptions; for patients with chronic kidney disease (particularly eGFR < 30 mL/min/1.73 m 2 ) or advanced liver disease, protein targets must be strictly individualized in consultation with renal or hepatology specialists [68,72].”
InfluentialAssociation of Patient Cost Sharing With Adherence to GLP-1RA and Adverse Health Outcomes
Zhang, D., Gencerliler, N., Mukhopadhyay, A., Blecker, S., Grams, M. E., Wright, D. R., Wang, V. H.-C., Rajan, A., Butt, E., Shin, J.-I., et al. (2025) · Diabetes Care · doi:10.2337/dc24-2746 · Cited by 14 · cited 1×
“A dose–response relationship exists between cost-sharing and adherence: patients in the highest out-of-pocket cost quartiles have significantly greater odds of nonadherence [57].”
Barana, L., De Fano, M., Cavallo, M., Manco, M., Prete, D., Fanelli, C. G., Porcellati, F., & Pippi, R. (2025) · Nutrients · doi:10.3390/nu18010131 · Cited by 13 · cited 1×
“Recent GLP-1-specific narrative consensus extends these recommendations to patients receiving incretin-based pharmacotherapy [71].”
von Haehling, S., Sato, R., Langer, H., Khan, M. S., Coats, A. J. S., Evans, W., Heymsfield, S., & Anker, S. D. (2025) · Journal of Cachexia, Sarcopenia and Muscle · doi:10.1002/jcsm.70147 · Cited by 10
Brain Activity Associated with Breakthrough Food Preoccupation in an Individual on Tirzepatide
Choi, W., Nho, Y.-H., Qiu, L., Chang, A., Campos, G., Seilheimer, R. L., Wilent, W. B., Bakalov, D., Firdous, N., Kerr, M., et al. (2025) · Nature Medicine · doi:10.1038/s41591-025-04035-5 · Cited by 10 · cited 2×
“Recent neuroimaging and behavioral studies indicate that GLP-1 RAs also suppress activity within the mesolimbic reward circuitry and modulate the default mode network, effectively reducing maladaptive food-related prospection, commonly described as “food noise” [32].”
Siudak, Z., Daniec, M., Szarpak, Ł., Tomaszewska, M., Kozela, M., & Dziewierz, A. (2025) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.16590 · Cited by 8 · cited 3×
“…on the same underlying data source but define and analyze distinct cohorts to address complementary stages of the patient journey—Siudak et al. [46] quantified persistence among adults who had already started therapy, whereas Dziewierz et al. [47] quantified initiation among the broader…”
InfluentialSelf-citationNutritional Approaches to Enhance GLP-1 Analogue Therapy in Obesity: A Narrative Review
Dias, D. D., Vasconcelos, A. R., Souza, A. C. R., Menezes, C. D., Silva, I. S. T. E., & Name, J. J. (2025) · Obesities · doi:10.3390/obesities5040088 · Cited by 8 · cited 1×
“…to inhibit gastric emptying, reducing fat load per meal is a physiologically plausible and commonly recommended strategy to reduce postprandial nausea and fullness during GLP-1 RA titration, although randomized dietary-modification trials specifically in GLP-1-treated cohorts are lacking [66,67].”
Kamrul-Hasan, A. B. M., Pappachan, J. M., Dutta, D., Nagendra, L., Kuchay, M. S., & Kapoor, N. (2025) · World Journal of Diabetes · doi:10.4239/wjd.v16.i4.101731 · Cited by 8
Obesity, cardiovascular and cerebrovascular disease: the role of GLP-1 receptor agonists
Tirandi, A., Montecucco, F., Carbone, F., & Liberale, L. (2024) · Polish Archives of Internal Medicine · doi:10.20452/pamw.16658 · Cited by 8
Kolli, R. T., Aoutla, S., Jyothi, N., Mohamed Kalifa, M. R. H., Raju, A., & Cheenikkal Muralidharan, K. (2025) · Cureus · doi:10.7759/cureus.94926 · Cited by 7
Wu, J., Perez, A., & Sullivan, P. W. (2025) · Journal of Managed Care & Specialty Pharmacy · doi:10.18553/jmcp.2025.31.10.1029 · Cited by 7
Who Wins the Battle Against Obesity? A Network Meta-Analysis Comparing Tirzepatide and Semaglutide
Bernardi, J. C., Cavalcante, D. V. S., Huntermann, R., Molinari, M. E., Zanon, L. Z., Khater, J., Gomez, V. A., & Fischer‐Bacca, C. O. (2026) · Journal of Diabetes · doi:10.1111/1753-0407.70192 · Cited by 5 · cited 1×
“Randomized clinical trials (RCTs) have consistently demonstrated efficacy profiles previously unattainable with non-surgical interventions [4,7,8].”
Wang, T., Cui, Y., & Liao, L. (2025) · Diabetes Therapy · doi:10.1007/s13300-024-01689-1 · Cited by 5
Expansion of Medicare Coverage for Medical Nutrition Therapy
Rowland, S., Hummel, S., Sikand, G., & Brandt, E. J. (2025) · JAMA Network Open · doi:10.1001/jamanetworkopen.2025.7716 · Cited by 4 · cited 1×
“This coverage gap creates a paradox in which patients receive highly potent pharmacotherapies without financial access to the nutritional expertise required to use them safely and effectively [65].”
Khan, T., Tsipas, S., Loustalot, F., Zasadzinski, L., Myftari, K., Goodman, A. B., & Wozniak, G. D. (2025) · Journal of the American Heart Association · doi:10.1161/jaha.125.043137 · Cited by 4 · cited 1×
“The market is characterized by high out-of-pocket costs, complex insurance utilization management, and recurrent supply shortages [27,40,41].”
Do GLP-1 Receptor Agonists Alter Brain Responses to Reward-Related Cues? A Systematic Review
Dang, V., Sambuco, N., Yammine, L., & Versace, F. (2026) · doi:10.64898/2026.01.31.702984 · Cited by 4 · cited 1×
“While these findings are hypothesis-generating rather than definitive, they suggest that GLP-1 therapies may not permanently remodel the deep neural architecture governing impulse control, meaning the pharmacological dampening of the reward pathway could be largely reversible [60].”
Nutritional Management in Functional Dyspepsia and Gastroparesis
Störsrud, S., Algera, J. P., & Törnblom, H. (2025) · Best Practice & Research Clinical Gastroenterology · doi:10.1016/j.bpg.2025.102079 · Cited by 3
Machado-Duque, M. E., Gaviria-Mendoza, A., Valladales-Restrepo, L. F., & Machado-Alba, J. E. (2025) · Drugs - Real World Outcomes · doi:10.1007/s40801-025-00518-6 · Cited by 2
Ali, M., Amirthalingam, P., Alshareef, H., Alqifari, S., Elsaid Hamdan, A., Alatawi, O., Hakami, F., Albalawi, N., & Aljabri, A. (2025) · Patient Preference and Adherence · doi:10.2147/ppa.s569096 · Cited by 2
Dziewierz, A., Rajtar-Salwa, R., Szarpak, L., Sojda, A., & Siudak, Z. (2025) · Archives of Medical Science · doi:10.5114/aoms/209719 · Cited by 2
Self-citationBrennan-Davies, A. H., & Lakey, S. (2025) · Cureus · doi:10.7759/cureus.97124 · Cited by 2
Shekouh, D., Behboodi, M., Varmazyar, M., Khodadadiyan, A., Jochin, P., & Bazrafshan drissi, H. (2026) · Obesity Surgery · doi:10.1007/s11695-026-08500-z · Cited by 1 · cited 3×
“Furthermore, landmark trials such as SELECT have confirmed significant reductions in major adverse cardiovascular events (MACE), establishing these agents as systemic disease-modifying therapies beyond glycemic and weight control [7,14,15].”
Perez-Belmonte, L. M., Prieto-Laín, N., & Gómez‐Huelgas, R. (2025) · Kardiologia Polska · doi:10.33963/v.phj.106670
Research works printed but not linked: 1
- (2005). Dietary Reference Intakes for Water, Potassium, Sodium, Chloride, and Sulfate, National Academies Press.
Cited by
Dziewierz, A., Kulicka, N., Łupina, K., Maruszak, N., Gałuszka, A., Domienik‐Karłowicz, J., Rulkiewicz, A., & Siudak, Z. (2026) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2026.113493
Self-citationKamrul-Hasan, A. B. M., Ashraf, H., Nagendra, L., Khalil, I., Chatterjee, S., Dutta, D., Haq, T., Alanazi, M. A., & Pappachan, J. M. (2026) · Obesity Science & Practice · doi:10.1002/osp4.70181 · Cited by 1
Metadata
- Authors
- Dziewierz, A., & Siudak, Z.
- Affiliations
- Jagiellonian University (PL)
- Jan Kochanowski University (PL)
- Corresponding author
- Siudak, Zbigniew
- Venue
- Nutrients
- Publisher
- MDPI AG
- Published
- 2026-05-30
- Volume
- 18
- Issue
- 11
- Pages
- 1761
- ISSN
- 2072-6643 (ISSN-L)
- PMC
- PMC13259006
- OpenAlex
- W7163024474
- Cited by
- 3
- References
- 74
- Citations by year
- 2026: 3
- FWCI
- 3.18
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Nutrients (publishedVersion, cc-by)
- PubMed (publishedVersion)
- PubMed Central (publishedVersion, cc-by)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Health Sciences › Medicine › Family Practice › Medication Adherence and Compliance
- Keywords
- GLP-1 receptor agonists, treatment persistence, medication adherence, type 2 diabetes, obesity, medical nutrition therapy, gastrointestinal intolerance, protein intake, lean mass loss, gastric emptying, cost barriers, integrated care, real-world effectiveness
- MeSH terms
- Glucagon-Like Peptide-1 Receptor Agonists, Adherence Interventions, Diabetes Mellitus, Type 2, Humans, Hypoglycemic Agents, Life Style, Obesity, Weight Loss, Nutrition Therapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.